Ali AYYILDIZ, Süleyman Barış KARTAL, Mürsel DAVARCI, Ahmet GÖKÇE, Eşref Oğuz GÜVEN, Mehmet İNCİ, Fatih Rüştü YALÇINKAYA, Mevlana Derya BALBAY

Th e impact of NIH-IV prostatitis on early post-operative outcomes of transurethral resection of the prostate in patients with symptomatic benign prostate hyperplasia

Amaç: Transüretral prostat rezeksiyonu (TURP) semptomatik benign prostat hiperplazisi (BPH) cerrahi tedavisinde halen altın standarttır. Kronik prostatit (KP) National Institute of Health -IV (NIH-IV) prostatın asemptomatik infl amasyonu olup histolojik örneklerde BPH ile sıkça birlikte bulunmaktadır. Bu çalışmada KP NIH-IV’ün semptomatik BPH nedeniyle yapılan TURP’ ların post operatif erken sonuçlarına etkisini incelenmesi amaçlanmıştırYöntem ve gereç: Adana Numune Eğitim ve Araştırma Hastanesinde 2004-2008 yılları arasında TURP yapılan 247 hastanın tıbbi kayıtları retrospektif olarak incelendi. Histopatolojiye göre saf BPH olanlar 1. grubu oluştururken KP ve BPH olanlar 2. grubu oluşturdular. Total prostat spesifi k antijen seviyesi (tPSA), Uluslararası Prostat Semptom Skoru (IPSS), tek soruluk yaşam kalitesi (QoL), maksimum akım hızı (Q max), sondalı kalma süresi, ve erken tekrar sondalama oranları ve süreleri ile birlikte post-op 90. gündeki IPSS, QoL, Qmax değerleri karşılaştırıldı. istatistiksel analiz Student t ve ki kare testleri ile SPSS® version 16 ile yapıldı. Bulgular: Preoperatif IPSS, Qmax, QoL, prostat hacimleri, tPSA ve sondalı kalma süreleri ortancaları grup 1 ve 2 arasında anlamlı farklılık göstermedi (P > 0,05). Tekrar sondalama oranları arasında anlamlı farklılık vardı (P < 0,05). Doksanıncı gün IPSS ve QoL ortancaları arasında anlamlı farklılık saptanırken (P < 0,05), Q max ortancaları arasında farklılık yoktu (P > 0,05). Sonuç: KP NIH-IV semptomatik BPH nedeniyle TURP yapılan hastaların subjektif post-op sonuçları ve tekrar sondalama sıklıkları üzerinde olumsuz etki göstermektedir.

NIH-IV kronik prostatitin semptomatik benign prostat hiperplazili hastaların transüretral prostat rezeksiyonu sonrası erken dönem sonuçlarına etkisi

Aim: Transurethral prostate resection (TURP) is still considered the gold standard in the treatment of symptomatic benign prostate hyperplasia (BPH). Category IV chronic prostatitis (CP) is described by the National Institute of Health (NIH-IV) as the asymptomatic infl ammation of the prostate and it may be detected along with benign prostate hyperplasia (BPH) during histological examinations of the prostate. In this study, we evaluate the impact of the presence of NIH-IV defi ned prostatitis on early post-operative outcomes of transurethral resection of the prostate. Materials and methods: Between 2004 and 2008, medical records of 247 patients who underwent TURP in Adana Numune Training and Research hospital were examined, retrospectively. Patients who had a histological diagnosis of only BPH were considered in Group 1 whereas Group 2 consisted of patients with both NIH-IV CP and BPH simultaneously. Factors such as total prostate specifi c antigen (tPSA) levels, International Prostate Symptom Scores (IPSS), singlequestion quality of life (QoL) assessments, maximum fl ow rates (Q max), residual urine volumes, catheterization times, re-catheterization rates, and the duration of re-catheterization were compared between these 2 groups. IPSS, QoL, and urofl owmetry measurements were compared between the 2 groups again at the third post-operative month. Statistical analysis with Student’s t and chi-square tests was performed with SPSS ® version 16. Results: Preoperatively, no statistically signifi cant diff erence was present between the 2 groups with respect to IPSS, Q max, QoL, prostate volume, tPSA, and mean catheterization time (P > 0.05); however, re-catheterization rates were signifi cantly diff erent (P < 0.05). While meaningful diff erence was found between 90th day IPSS and QoL medians (P < 0.05), there was no diff erence in Q max medians (P > 0.05). Conclusion: NIH-IV chronic prostatitis shows negative eff ects on the subjective post-operative results and recatheterization frequency of BPH patients that have undergone TURP.

PDF

___

1. Nickel JC. Th e overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis. Curr Opin Urol 2006; 16: 5-10.
2. Emberton M, Cornel EB, Bassi PF, Fourcade RO, Gómez JM, Castro R. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract 2008; 62: 1076-86.
3. Mishra VC, Allen DJ, Nicolaou C, Sharif H, Hudd C, Karim OM et al. Does intraprostatic infl ammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int 2007; 100: 327-31.
4. Kramer G, Marberger M. Could infl ammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 2006; 16: 25-9.
5. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus defi nition and classifi cation of prostatitis. JAMA 1999; 282: 236-7.
6. Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA et al. Distribution of infl ammation, pre-malignant lesions, incidental carcinoma in histological confi rmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43: 164-75.
7. Kohnen PW, Drach GW. Patterns of infl ammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol 1979;121: 755-60.
8. Tunuguntla HS, Evans CP. Minimally invasive therapies for benign prostatic hyperplasia. World J Urol. 2002; 20: 197-206.
9. Zlotta AR, Djavan B. Minimally invasive therapies for benign prostatic hyperplasia in the new millennium: long-term data. Curr Opin Urol 2002; 12: 7-14.
10. Stancik I, Lüft enegger W, Klimpfi nger M, Müller MM, Hoeltl W. Eff ect of NIH-IV prostatitis on free and free-to-total PSA. Eur Urol 2004; 46: 760-4.
11. Madersbacher S, Marberger M. Is transurethral resection of the prostate still justifi ed? BJU Int 1999; 83: 227-37.
12. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic infl ammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010; 1; 33: 475-88.
13. Nickel JC. Infl ammation and benign prostatic hyperplasia. Urol Clin North Am 2008; 35: 109-15.
14. Kirby RS. Th e natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology 2000; 56: 3-6.
15. Arrighi HM, Guess HA, Metter EJ, Fozard JL. Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate 1990; 16: 253-61.
16. Girman CJ, Panser LA, Chute CG, Oesterling JE, Barrett DM, Chen CC et al. Natural history of prostatism: urinary fl ow rates in a community-based study. J Urol 1993; 150: 887-92.
17. Reich O, Gratzke C, Stief CG. Techniques and long-term results of surgical procedures for BPH. Eur Urol 2006; 49: 970-8.
18. Nickel JC, Roehrborn CG, O’Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. Examination of the relationship between symptoms of prostatitis and histological infl ammation: baseline data from the REDUCE chemoprevention trial. J Urol 2007; 178: 896-900.
19. Nickel JC, Roehrborn CG, O’Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. Th e relationship between prostate infl ammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 2008; 54: 1379-84.
20. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW et al. Medical Th erapy of Prostatic Symptoms (MTOPS) Research Group. Th e long-term eff ect of doxazosin, fi nasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98.
21. Nickel JC. Prostatic infl ammation in benign prostatic hyperplasia - the third component? Can J Urol 1994; 1: 1-4.
22. Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Th ird National Health and Nutrition Examination Survey (NHANES III). Prostate 2005;62: 27-33.